greeksoup/ stock research

Privia Health Group, Inc.: Q3 FY2025 earnings call

What management said about Q3 FY2025, from the documents filed with the SEC on 6 November 2025: press release. Guidance figures: 7 raised, 1 new, 1 kept. The quarter’s numbers.

Key takeaways

  • Revenue and operating income rose: Third-quarter revenue was $580.4 million, up 32.5% from $437.9 million, and operating income was $14.4 million, up 147.8% from $5.8 million. Source
  • Adjusted EBITDA up 61.6%: Adjusted EBITDA was $38.2 million, up 61.6% from $23.6 million, with a margin of 30.5% against 23.3% a year earlier. Source
  • MSSP shared savings up 32.6%: The company's nine ACOs reported aggregate 2024 MSSP shared savings of $234.1 million, up 32.6% from 2023. Source
  • Practice Collections up 27.1%: Practice Collections were $940.4 million, up 27.1% from $739.9 million; the company says collections include Non-Owned Medical Groups. Source
  • Pro forma cash of $409.9 million: Pro forma for about $68.5 million received from CMS in October and the expected $100 million Evolent payment, cash would be $409.9 million. Source
  • Agreement to buy Evolent's ACO business: The agreement covers an ACO business that cares for over 120,000 attributed lives through the MSSP and commercial and Medicare Advantage programs. Source
  • Attributed lives to exceed 1.5 million: With the transaction, the company would serve more than 1.5 million attributed lives in value-based care arrangements across commercial, Medicare, Medicare Advantage and Medicaid. Source
  • Consideration of $100 million plus contingent amount: The company will pay $100 million in cash at closing from its balance sheet, and up to $13 million more depending on final 2025 MSSP performance. Source
  • Guidance excludes pending Evolent deal: The updated full-year guidance does not include any effect from the pending Evolent ACO transaction. Source

“Very Strong Third Quarter and Year-to-Date Performance Across the Business”

Privia Health Group, Inc., press release

Guidance

AreaPeriodFigureAgainst last quarter
Implemented Providers SourceFY 20255,300 - 5,350Raised from 5,200 - 5,300 initial; high end at 8.7.25
Attributed Lives SourceFY 20251,400,000 - 1,425,000Raised from 1,300,000 - 1,400,000 initial; high end at 8.7.25
Practice Collections ($ millions) SourceFY 2025$3,450 - $3,500Raised from $3,150 - $3,250 initial; above high end at 8.7.25
GAAP Revenue ($ millions) SourceFY 2025$2,050 - $2,100Raised from $1,800 - $1,900 initial; above high end at 8.7.25
Care Margin ($ millions) SourceFY 2025$455 - $460Raised from $435 - $445 initial; high end at 8.7.25
Platform Contribution ($ millions) SourceFY 2025$230 - $235Raised from $208 - $218 initial; above high end at 8.7.25
Adjusted EBITDA ($ millions) SourceFY 2025$118 - $121Raised from $105 - $110 initial; above high end at 8.7.25
Adjusted EBITDA conversion to free cash flow SourceFY 2025more than 80%Kept
Cash and cash equivalents at year-end SourceEnd of FY 2025, pro forma for ACO transactionat least $410 millionNew

What changed from last quarter

  • Guidance raised: Full-year 2025 guidance was raised for implemented providers, attributed lives, Practice Collections, GAAP revenue, Care Margin, Platform Contribution and Adjusted EBITDA. Source
  • New guidance: A year-end 2025 cash figure of at least $410 million, pro forma for the ACO transaction, appears in this release for the first time. Source
  • New: The company signed an agreement to acquire an ACO business from Evolent Health; this deal was not in the prior release. Source

Results and growth drivers

  • Revenue and operating income rose: Third-quarter revenue was $580.4 million, up 32.5% from $437.9 million, and operating income was $14.4 million, up 147.8% from $5.8 million. Source
  • Adjusted EBITDA up 61.6%: Adjusted EBITDA was $38.2 million, up 61.6% from $23.6 million, with a margin of 30.5% against 23.3% a year earlier. Source
  • Nine-month Adjusted EBITDA up 43.5%: For the nine months, Adjusted EBITDA was $94.1 million against $65.6 million, an increase of 43.5%. Source
  • Diluted EPS rose to five cents: Net income per diluted share was $0.05 against $0.03, and non-GAAP adjusted diluted EPS was $0.29 against $0.20, up 45.0%. Source

Segments, footprint and regions

  • Presence in 15 states: The company reports a presence in 15 states and the District of Columbia. Source
  • Arizona entry and prior cash: The prior release noted cash of $390.1 million and no debt at June 30, 2025, after $95 million was deployed for an IMS transaction in Arizona.
  • Physician reach across the platform: The company says it rewards 5,200+ physicians and advanced practitioners for delivering high-value care. Source

“Privia Health raised its full-year 2025 outlook as follows”

Privia Health Group, Inc., press release

Value-based care and shared savings

  • Attributed lives reached 1.41 million: Value-based care attributed lives reached 1,406,000 at September 30, up 12.8% from 1,247,000 a year earlier. Source
  • MSSP shared savings up 32.6%: The company's nine ACOs reported aggregate 2024 MSSP shared savings of $234.1 million, up 32.6% from 2023. Source
  • Second-quarter attributed lives comparison: The second-quarter release showed 1,382,000 attributed lives at June 30, 2025, up 15.2% from 1,200,000 a year earlier.

Costs and margins

  • Provider expense rose to $455.2 million: Provider expense was $455.2 million against $336.5 million a year earlier, and cost of platform was $61.4 million against $56.1 million. Source
  • Platform and EBITDA margins higher: Platform Contribution margin was 56.3% against 49.6%, and Adjusted EBITDA margin was 30.5% against 23.3%, as the company defines them. Source
  • General and administrative costs up: General and administrative expense was $39.6 million against $30.7 million; sales and marketing was $7.0 million in both periods. Source
  • Stock compensation expense increased: Net income included $19.0 million of non-cash stock compensation expense in the quarter, against $15.1 million a year earlier. Source

“Strong results in the Medicare Shared Savings Program (MSSP) and other value-based care arrangements for 2024 performance year”

Privia Health Group, Inc., press release

Demand, pipeline and revenue mix

  • Same-store growth and new providers: Management cited same-store growth and new provider additions among the third-quarter highlights. Source
  • Practice Collections up 27.1%: Practice Collections were $940.4 million, up 27.1% from $739.9 million; the company says collections include Non-Owned Medical Groups. Source
  • Capitated and shared savings revenue rose: Capitated revenue was $90.9 million and shared savings revenue was $80.0 million, against $53.4 million and $47.4 million a year earlier. Source
  • Nine-month Practice Collections up 19.6%: For the nine months, Practice Collections were $2,601.9 million against $2,175.6 million a year earlier. Source

Capital, cash and balance sheet

  • Cash and no debt at quarter-end: The company held $441.4 million of cash and cash equivalents and no debt at September 30, 2025. Source
  • Pro forma cash of $409.9 million: Pro forma for about $68.5 million received from CMS in October and the expected $100 million Evolent payment, cash would be $409.9 million. Source
  • Operating cash flow for nine months: Net cash provided by operating activities was $35.9 million for the nine months, against $34.5 million a year earlier. Source
  • Receivables higher than year-end: Accounts receivable were $499.0 million at September 30, against $316.2 million at December 31, 2024. Source

Evolent ACO acquisition

  • Agreement to buy Evolent's ACO business: The agreement covers an ACO business that cares for over 120,000 attributed lives through the MSSP and commercial and Medicare Advantage programs. Source
  • Attributed lives to exceed 1.5 million: With the transaction, the company would serve more than 1.5 million attributed lives in value-based care arrangements across commercial, Medicare, Medicare Advantage and Medicaid. Source
  • Consideration of $100 million plus contingent amount: The company will pay $100 million in cash at closing from its balance sheet, and up to $13 million more depending on final 2025 MSSP performance. Source

Guidance basis and reporting

  • Guidance excludes pending Evolent deal: The updated full-year guidance does not include any effect from the pending Evolent ACO transaction. Source
  • Forward non-GAAP measures not reconciled: Management has not reconciled its forward-looking non-GAAP measures to the most directly comparable GAAP measures, citing unpredictable items. Source

Coming up, as management said on 6 November 2025

  • Evolent ACO closing expected Q4 2025: Closing is expected in the fourth quarter of 2025, subject to regulatory approvals and customary closing conditions. Source
  • Deal to add to 2026 Adjusted EBITDA: Management expects the acquisition to make a positive contribution to Adjusted EBITDA in 2026. Source

Earlier plans management reported on

  • Not stated: Earlier guidance included the Arizona market entry and assumed no other new business development activity.
  • Not stated: Earlier guidance expected de minimis capital expenditures in 2025; the third-quarter release does not restate this.

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.